KDM5A inhibitors, including JIB 04, CPI-455, and GSK-J4, have been shown to inhibit proliferation and induce apoptosis in TMZ-resistant GBM cells [222], indicating a complex, context-dependent role for KDM5A in GBM progression that requires further in vivo studies. This evidence concerns the gene KDM5A and glioblastoma.